Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

There was also a positive sign for investors worried about the rapid pace at which the company has been burning through its ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

Mixed options sentiment in Moderna (MRNA), with shares down $1.15 near $25.56. Options volume running well above average with 49k contracts traded ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

Has BridgeBio's business model worked? How are executives at Moderna dealing with the company's slump? Find out on the new episode of "The Readout LOUD." ...

Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...

The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...